Evidence map›Paper›PMID 32134190›Full record

ArticleBiotechnology progress2020

Transfection of glycoprotein encoding mRNA for swift evaluation of N-glycan engineering strategies.

Nina Bydlinski, Michael T Coats, Daniel Maresch, Richard Strasser, Nicole Borth

Abstract read
In one paragraph

Article in Biotechnology progress, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. CRISPR Technologies in Chinese Hamster Ovary Cell Line Engineering.International journal of molecular sciences · 2023
    Review
  2. Codon optimization regulates IgG3 and IgM expression and glycosylation inFrontiers in bioengineering and biotechnology · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nina BydlinskiDepartment of Biotechnology, BOKU University of Natural Resources and Life Sciences, Vienna, Austria.ORCID 0000-0001-9048-6929
Michael T CoatsDepartment of Biotechnology, BOKU University of Natural Resources and Life Sciences, Vienna, Austria.
Daniel MareschDepartment of Chemistry, BOKU University of Natural Resources and Life Sciences, Vienna, Austria.
Richard StrasserDepartment of Applied Genetics and Cell Biology, BOKU University of Natural Resources and Life Sciences, Vienna, Austria.ORCID 0000-0001-8764-6530
Nicole BorthDepartment of Biotechnology, BOKU University of Natural Resources and Life Sciences, Vienna, Austria.ORCID 0000-0001-6324-9338

Funding

Austrian Science Fund FWF W 1224
6 · The paper itself

Abstract

N-glycosylation is defined as a key quality attribute for the majority of complex biological therapeutics. Despite many N-glycan engineering efforts, the demand to generate desired N-glycan profiles that may vary for different proteins in a reproducible manner is still difficult to fulfill in many cases. Stable production of homogenous structures with a more demanding level of processing, for instance high degrees of branching and terminal sialylation, is particularly challenging. Among many other influential factors, the level of productivity can steer N-glycosylation towards less mature N-glycan structures. Recently, we introduced an mRNA transfection system capable of elucidating bottlenecks in the secretory pathway by stepwise increase of intracellular model protein mRNA load. Here, this system was applied to evaluate engineering strategies for enhanced N-glycan processing. The tool proves to indeed be valuable for a quick assessment of engineering approaches on the cellular N-glycosylation capacity at high productivity. The gene editing approaches tested include overexpression of key Golgi-resident glycosyltransferases, partially coupled with multiple gene deletions. Changes in galactosylation, sialylation, and branching potential as well as N-acetyllactosamine formation were evaluated.

Indexed as

Protein EngineeringAnimalsCHO CellsCricetinaeCricetulusGlycoproteinsGlycosylationPolysaccharidesRNA, MessengerTransfectionGlycoproteinsPolysaccharidesRNA, Messenger

Identifiers

PMID32134190
PMCPMC7507192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.